Related Experiment Video
Updated: Jan 13, 2026

Validation of a Mouse Model to Disrupt LINC Complexes in a Cell-specific Manner
Published on: December 10, 2015
Mechanistic study of LINC01296 mediating TRIP13 regulation of neuroblastoma progression
Yuanbin He1,2, Jiansen Fan1,2, Yu Lin1,2
1Department of Paediatric Surgery, Fujian Children's Hospital (Fujian Branch of Shanghai Children's Medical Center), Fuzhou, China.
Background:
Neuroblastoma (NB) is an embryonic cancer arising from neural crest cells. Long non-coding RNA (lncRNA) plays an important role in the development of tumors. Several studies have reported that LINC01296 and thyroid hormone receptor interacting protein 13 (TRIP13) acts as oncogenic regulators of cancer. However, their deep specific biological mechanisms in tumor metastasis are not known. Here, we aimed to elucidate whether LINC01296 or TRIP13 drives NB proliferation and progression, and to assess their potential as therapeutic targets.
Methods:
In this study, we utilized the NB cell line SK-N-SH to investigate the roles of LINC01296 and TRIP13 by bacterial transformation and polymerase chain reaction (PCR) verification. Cells were infected with lentivirus, and fluorescence expression was monitored. Total RNA was extracted for reverse transcription quantitative PCR (RT-qPCR). Cell proliferation was assessed by using Cell Counting Kit-8 (CCK-8) assay. Migration was evaluated using wound-healing assays, and invasion was tested via Transwell with Matrigel-coated chambers. Apoptosis was analyzed by flow cytometry. For in vivo studies, non-obese diabetic/severe combined immunodeficiency (NOD/scid) mice were subcutaneously injected with 1×107 cells/mL suspended in Matrigel. Tumor growth was measured every 2 days for 23 days; tissues were harvested for paraffin sections or stored at -80 ℃. Immunohistochemistry (IHC) involved antigen retrieval, blocking with 5% normal serum, primary antibody incubation, and counterstaining. Confocal microscopy was used for imaging.
Results:
In this study, we found that compared with negative control (NC) group, overexpression of LINC01296 (OE-LINC01296) or TRIP13 (OE-TRIP13) both promoted the proliferation, migration and invasion of SK-N-SH cells, while inhibiting apoptosis; and vice versa. In addition, we further demonstrated that LINC01296 stabilised knockdown via short hairpin RNA (shRNA) (sh-LINC01296) + OE-TRIP13, and TRIP13 stabilised knockdown via shRNA (sh-TRIP13) + OE-LINC01296 decreased SK-N-SH cell proliferation, migration and invasion, while promoting apoptosis. We also established a subcutaneous transplantation tumor model in NB NOD/scid mice, and sh-LINC01296 or sh-TRIP13 inhibited tumor growth in mice, and the tumor growth in the sh-LINC01296 + OE-TRIP13 group and the sh-TRIP13 + OE-LINC01296 group was between the NC group and the sh-LINC01296 or sh-TRIP13 group.
Conclusions:
These results suggest that LINC01296 may play a role as an oncogene in the development of tumorigenesis in NB by mediating TRIP13, and provide a marker for the prognosis of NB.
Insights
Long non-coding RNA LINC01296 and TRIP13 promote neuroblastoma (NB) progression by enhancing proliferation and metastasis. Targeting LINC01296 or TRIP13 may offer new therapeutic strategies for NB treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Neuroblastoma (NB) is a pediatric cancer originating from neural crest cells.
- Long non-coding RNAs (lncRNAs) are implicated in tumor development.
- LINC01296 and thyroid hormone receptor interacting protein 13 (TRIP13) are known oncogenic regulators, but their specific roles in NB metastasis are unclear.
Purpose of the Study:
- To investigate the roles of LINC01296 and TRIP13 in neuroblastoma (NB) proliferation and progression.
- To elucidate the underlying biological mechanisms of LINC01296 and TRIP13 in NB metastasis.
- To assess the potential of LINC01296 and TRIP13 as therapeutic targets for NB.
Main Methods:
- Utilized NB cell line SK-N-SH for in vitro studies.
- Employed lentivirus infection, RT-qPCR, CCK-8 assay, wound-healing assay, Transwell invasion assay, and flow cytometry for apoptosis analysis.
- Established a subcutaneous xenograft tumor model in NOD/scid mice for in vivo validation.
Main Results:
- Overexpression of LINC01296 or TRIP13 promoted NB cell proliferation, migration, and invasion while inhibiting apoptosis.
- Knockdown of LINC01296 or TRIP13, especially in combination with overexpression of the other, reduced NB cell proliferation, migration, and invasion, and promoted apoptosis.
- In vivo studies confirmed that LINC01296 and TRIP13 knockdown inhibited tumor growth in mice.
Conclusions:
- LINC01296 acts as an oncogene in NB tumorigenesis, potentially by mediating TRIP13.
- LINC01296 and TRIP13 play crucial roles in promoting NB cell proliferation, migration, invasion, and inhibiting apoptosis.
- These findings suggest LINC01296 and TRIP13 as potential therapeutic targets and prognostic markers for NB.

